Ralph Passarella, Reify Health CEO

A uni­corn bags an­oth­er $220M to fund its plans to up­end the clin­i­cal tri­al process

The fo­cus on de­cen­tral­ized tri­als amid the pan­dem­ic has led in­vestors to make some big bets on com­pa­nies promis­ing to shake up the con­tract re­search space. Reify Health is the lat­est, com­ing away with $220 mil­lion to end what it calls the “sit and wait” pe­ri­od dur­ing tri­al en­roll­ment.

“What we’re do­ing, and the fu­ture of clin­i­cal tri­als over­all, goes be­yond de­cen­tral­ized tri­als,” ex­ec­u­tive chair­man Michael Lin said in a state­ment. “We need to have a glob­al health­care sys­tem proac­tive­ly reach­ing out to pa­tients every­where and mo­bi­liz­ing the re­sources nec­es­sary to bring tri­als to them.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.